138 related articles for article (PubMed ID: 16513422)
1. EAE: pitfalls outweigh virtues of screening potential treatments for multiple sclerosis.
Ransohoff RM
Trends Immunol; 2006 Apr; 27(4):167-8. PubMed ID: 16513422
[No Abstract] [Full Text] [Related]
2. Virtues and pitfalls of EAE for the development of therapies for multiple sclerosis.
Steinman L; Zamvil SS
Trends Immunol; 2005 Nov; 26(11):565-71. PubMed ID: 16153891
[TBL] [Abstract][Full Text] [Related]
3. The translation of drug efficacy from in vivo models to human disease with special reference to experimental autoimmune encephalomyelitis and multiple sclerosis.
Bolton C
Inflammopharmacology; 2007 Oct; 15(5):183-7. PubMed ID: 17943249
[TBL] [Abstract][Full Text] [Related]
4. Steroid protection in the experimental autoimmune encephalomyelitis model of multiple sclerosis.
Garay L; Gonzalez Deniselle MC; Gierman L; Meyer M; Lima A; Roig P; De Nicola AF
Neuroimmunomodulation; 2008; 15(1):76-83. PubMed ID: 18667803
[TBL] [Abstract][Full Text] [Related]
5. Preclinical assessment of therapeutic antibodies against human CD40 and human interleukin-12/23p40 in a nonhuman primate model of multiple sclerosis.
't Hart BA; Hintzen RQ; Laman JD
Neurodegener Dis; 2008; 5(1):38-52. PubMed ID: 18075274
[TBL] [Abstract][Full Text] [Related]
6. Intensive suppression of experimental allergic encephalomyelitis (EAE) by serum thymic factor and therapeutic implication for multiple sclerosis.
Nagai Y; Osanai T; Sakakibara K
Jpn J Exp Med; 1982 Aug; 52(4):213-9. PubMed ID: 6983610
[No Abstract] [Full Text] [Related]
7. Treatment with rapamycin ameliorates clinical and histological signs of protracted relapsing experimental allergic encephalomyelitis in Dark Agouti rats and induces expansion of peripheral CD4+CD25+Foxp3+ regulatory T cells.
Donia M; Mangano K; Amoroso A; Mazzarino MC; Imbesi R; Castrogiovanni P; Coco M; Meroni P; Nicoletti F
J Autoimmun; 2009 Sep; 33(2):135-40. PubMed ID: 19625166
[TBL] [Abstract][Full Text] [Related]
8. Strain-dependent effects of probiotic lactobacilli on EAE autoimmunity.
Maassen CB; Claassen E
Vaccine; 2008 Apr; 26(17):2056-7. PubMed ID: 18378048
[TBL] [Abstract][Full Text] [Related]
9. Arraying autoimmunity treatment.
Sercarz EE
Nat Biotechnol; 2003 Sep; 21(9):1017-9. PubMed ID: 12949565
[No Abstract] [Full Text] [Related]
10. Mitoxantrone in multiple sclerosis.
Neuhaus O; Kieseier BC; Hartung HP
Adv Neurol; 2006; 98():293-302. PubMed ID: 16400840
[No Abstract] [Full Text] [Related]
11. Quinpramine: revival of old anti-inflammatory principles in multiple sclerosis?
Haghikia A; Gold R
Exp Neurol; 2009 Jun; 217(2):240-1. PubMed ID: 19361499
[No Abstract] [Full Text] [Related]
12. Brain penetration of the oral immunomodulatory drug FTY720 and its phosphorylation in the central nervous system during experimental autoimmune encephalomyelitis: consequences for mode of action in multiple sclerosis.
Foster CA; Howard LM; Schweitzer A; Persohn E; Hiestand PC; Balatoni B; Reuschel R; Beerli C; Schwartz M; Billich A
J Pharmacol Exp Ther; 2007 Nov; 323(2):469-75. PubMed ID: 17682127
[TBL] [Abstract][Full Text] [Related]
13. Nerve growth factor prevents demyelination, cell death and progression of the disease in experimental allergic encephalomyelitis.
Parvaneh Tafreshi A
Iran J Allergy Asthma Immunol; 2006 Dec; 5(4):177-81. PubMed ID: 17237570
[TBL] [Abstract][Full Text] [Related]
14. Multiple sclerosis: human model for EAE?
Hohlfeld R
Eur J Immunol; 2009 Aug; 39(8):2036-9. PubMed ID: 19672899
[TBL] [Abstract][Full Text] [Related]
15. The value of animal models for drug development in multiple sclerosis.
Friese MA; Montalban X; Willcox N; Bell JI; Martin R; Fugger L
Brain; 2006 Aug; 129(Pt 8):1940-52. PubMed ID: 16636022
[TBL] [Abstract][Full Text] [Related]
16. Glucocorticoids in multiple sclerosis and experimental autoimmune encephalomyelitis.
Reichardt HM; Gold R; Lühder F
Expert Rev Neurother; 2006 Nov; 6(11):1657-70. PubMed ID: 17144780
[TBL] [Abstract][Full Text] [Related]
17. A potential role for estrogen in experimental autoimmune encephalomyelitis and multiple sclerosis.
Offner H; Polanczyk M
Ann N Y Acad Sci; 2006 Nov; 1089():343-72. PubMed ID: 17261780
[TBL] [Abstract][Full Text] [Related]
18. Are current disease-modifying therapeutics in multiple sclerosis justified on the basis of studies in experimental autoimmune encephalomyelitis?
Farooqi N; Gran B; Constantinescu CS
J Neurochem; 2010 Nov; 115(4):829-44. PubMed ID: 20807309
[TBL] [Abstract][Full Text] [Related]
19. Evaluating the validity of animal models for research into therapies for immune-based disorders.
't Hart BA; Amor S; Jonker M
Drug Discov Today; 2004 Jun; 9(12):517-24. PubMed ID: 15183159
[TBL] [Abstract][Full Text] [Related]
20. The role of neurotrophic factors in the pathology and treatment of multiple sclerosis.
Mirowska-Guzel D
Immunopharmacol Immunotoxicol; 2009; 31(1):32-8. PubMed ID: 18792835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
